Pulse Biosciences (Pulse Biosciences) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Pulse Biosciences is: No Data: Cannot be evaluated.

Competitive Comparison of Pulse Biosciences's Risk Assessment

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulse Biosciences's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Risk Assessment falls into.

Pulse Biosciences (NAS:PLSE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Pulse Biosciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulse Biosciences (Pulse Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

6L8:Germany

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Executives

Robert W Duggan	director, 10 percent owner	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy	officer: Chief Commercial Officer	50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner	officer: CFO & EVP Admin. and Finance	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray	director	C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono	director
Ed Ebbers	officer: EVP & GM, Dermatology	3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D	director	C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg	director	12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow	officer: CFO & SVP Admin. and Finance	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588